行情

FLXN

FLXN

Flexion
NASDAQ

实时行情|Nasdaq Last Sale

17.51
-0.32
-1.79%
已收盘, 16:16 01/17 EST
开盘
18.01
昨收
17.83
最高
18.28
最低
17.35
成交量
103.56万
成交额
--
52周最高
22.98
52周最低
8.76
市值
6.68亿
市盈率(TTM)
-4.2422
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FLXN 新闻

  • 沪指下跌1.41% IMF上调2020年中国经济增长预期
  • 新浪财经.32分钟前
  • 斯巴鲁CEO:美国人对电动汽车不太感兴趣 除了特斯拉
  • TechWeb.3小时前
  • 联合国:2019全球观光业成长放缓 经济降温系主因
  • 中国新闻网.3小时前
  • 资金意外流出 瑞银下调盈利能力和成本目标
  • 新浪美股.3小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

FLXN 简况

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
展开

Webull提供Flexion Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。